Malcolm A. Smith
A5046943976- Acute Lymphoblastic Leukemia research
- Neuroblastoma Research and Treatments
- Acute Myeloid Leukemia Research
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- Childhood Cancer Survivors' Quality of Life
- Cancer therapeutics and mechanisms
- Sarcoma Diagnosis and Treatment
- CAR-T cell therapy research
- Cancer Genomics and Diagnostics
- Mycobacterium research and diagnosis
- Protein Degradation and Inhibitors
- Virus-based gene therapy research
- Cancer, Hypoxia, and Metabolism
- Renal and related cancers
- Chronic Myeloid Leukemia Treatments
- Glioma Diagnosis and Treatment
- Amphibian and Reptile Biology
- Ubiquitin and proteasome pathways
- Pharmaceutical studies and practices
- Epigenetics and DNA Methylation
- Cancer Research and Treatments
- Chronic Lymphocytic Leukemia Research
- PARP inhibition in cancer therapy
- Computational Drug Discovery Methods
National Cancer Institute
2016-2025
Cisco Systems (China)
2025
Hospital of the University of Pennsylvania
2025
National Institutes of Health
2013-2024
University of Virginia
2024
Center for Cancer Research
2011-2023
Children's Hospital of Philadelphia
2007-2023
Lincoln University - Pennsylvania
2021-2023
Cisco College
2023
Health Education North West
2023
Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity neuroblastoma such is enhanced when ch14.18 combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2. We conducted study to determine whether adding GM-CSF, interleukin-2 standard isotretinoin therapy after intensive multimodal would improve outcomes in high-risk neuroblastoma.Patients who had response...
Despite best current therapy, up to 20% of pediatric patients with acute lymphoblastic leukemia (ALL) have a relapse. Recent genomewide analyses identified high frequency DNA copy-number abnormalities in ALL, but the prognostic implications these not been defined.We studied cohort 221 children high-risk B-cell-progenitor ALL use single-nucleotide-polymorphism microarrays, transcriptional profiling, and resequencing samples obtained at diagnosis. Children known very-high-risk subtypes (i.e.,...
Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL) is characterized by a gene-expression profile similar to that of BCR–ABL1–positive ALL, alterations lymphoid transcription factor genes, and poor outcome. The frequency spectrum genetic in Ph-like ALL its responsiveness tyrosine kinase inhibition are undefined, especially adolescents adults.
This report provides an overview of current childhood cancer statistics to facilitate analysis the impact past research discoveries on outcome and provide essential information for prioritizing future directions.Incidence survival data cancers came from Surveillance, Epidemiology, End Results 9 (SEER 9) registries, mortality were based deaths in United States that reported by states Centers Disease Control Prevention underlying cause.Childhood incidence rates increased significantly 1975...
PURPOSE To define more uniform criteria for risk-based treatment assignment children with acute lymphoblastic leukemia (ALL), the Cancer Therapy Evaluation Program (CTEP) of National Institute (NCI) sponsored a workshop in September 1993. Participants included representatives from Childrens Group (CCG), Pediatric Oncology (POG), Dana-Farber (DFCI), St Jude Children's Research Hospital (SJCRH), and CTEP. METHODS Workshop participants presented reviewed data ALL clinical trials, using weighted...
Abstract Analysis of molecular aberrations across multiple cancer types, known as pan-cancer analysis, identifies commonalities and differences in key biological processes that are dysregulated cells from diverse lineages. Pan-cancer analyses have been performed for adult 1,2,3,4 but not paediatric cancers, which commonly occur developing mesodermic rather than epithelial tissues 5 . Here we present a study somatic alterations, including single nucleotide variants, small insertions or...
Increased attention has been directed toward the long-term health outcomes of survivors childhood cancer. To facilitate such research, a multi-institutional consortium established Childhood Cancer Survivor Study (CCSS), large, diverse, and well-characterized cohort 5-year adolescent cancer.Eligibility for CCSS included selected group cancer diagnoses prior to age 21 years between 1970-1986 survival at least 5 years.A total 20,276 eligible subjects were identified from 25 contributing...
Pediatric acute lymphoblastic leukemia (ALL) is a heterogeneous disease consisting of distinct clinical and biological subtypes that are characterized by specific chromosomal abnormalities or gene mutations. Mutation genes encoding tyrosine kinases uncommon in ALL, with the exception Philadelphia chromosome-positive where t(9,22)(q34;q11) translocation encodes constitutively active BCR-ABL1 kinase. We recently identified poor prognostic subgroup pediatric BCR-ABL1-negative ALL patients...
We chose to examine the impact of socioeconomic factors on accrual National Cancer Institute (NCI)-sponsored cancer treatment trials.We estimated geographic and demographic burden in United States then identified 24,332 patients accrued NCI-sponsored trials during a 12-month period. Next, we examined by age, sex, residence, health insurance status, maintenance organization market penetration, several proxy measures availability an oncologist, presence hospital with approved multidisciplinary...
BACKGROUND To evaluate whether progress continues in identifying more effective treatments for children and adolescents with cancer, the authors examined both overall disease‐specific childhood cancer mortality rates United States, focusing on data from 2000 to 2010. METHODS Age‐adjusted US trends 1975 2010 were estimated using joinpoint regression analysis. Analyses of annual percentage change (APC) performed same diagnostic groupings period restricted through ages <20 years, <15 15...
No approved therapies exist for inoperable plexiform neurofibromas in patients with neurofibromatosis type 1.
Abstract Background The Pediatric Preclinical Testing Program (PPTP) is an initiative supported by the National Cancer Institute (NCI) to identify novel therapeutic agents that may have significant activity against childhood cancers. PPTP has established panels of cancer xenografts and cell lines be used for in vivo vitro testing. These include Wilms tumor, sarcomas (rhabdomyosarcoma, Ewing sarcoma, osteosarcoma), neuroblastoma, brain tumors (glioblastoma, ependymoma, medulloblastoma),...
BACKGROUND: During the 1980s, incidence of primary malignant brain and other central nervous system tumors (hereafter called cancer) was reported to be increasing among all age groups in United States, while mortality declining for persons younger than 65 years. We analyzed these data provide updates on trends cancer States examine patterns search their causes. METHODS: Data incidence, overall according histology anatomic site, relative survival were obtained from Surveillance, Epidemiology,...
Future progress in improving cancer therapy can be expedited by better prioritization of new treatments for phase III evaluation. Historically, II trials have been key components the process. There has a long-standing interest using with randomization against standard-treatment control arm or an additional experimental to provide greater assurance than afforded comparison historic controls that agent regimen is promising and warrants further Relevant trial designs developed utilized include...
Abstract There is incomplete understanding of genetic heterogeneity and clonal evolution during cancer progression. Here we use deep whole-exome sequencing to describe the architecture 20 pediatric B-acute lymphoblastic leukaemias from diagnosis relapse. We show that diversity comparable at relapse survival not associated with mutation burden. Six pathways were frequently mutated, NT5C2 , CREBBP WHSC1 TP53 USH2A NRAS IKZF1 mutations enriched Half had multiple subclonal in a pathway or gene...